ADMA Biologics Inc (NASDAQ:ADMA) was upgraded by stock analysts at Raymond James Financial, Inc. from a “market perform” rating to an “outperform” rating in a research report issued on Tuesday. The brokerage currently has a $5.00 price target on the biotechnology company’s stock. Raymond James Financial, Inc.’s price target suggests a potential upside of 101.61% from the company’s current price.

Separately, ValuEngine downgraded ADMA Biologics from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st.

ADMA Biologics (ADMA) opened at $2.48 on Tuesday. ADMA Biologics has a 52 week low of $2.01 and a 52 week high of $6.88. The company has a debt-to-equity ratio of 2.26, a current ratio of 2.36 and a quick ratio of 1.35.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings results on Friday, August 11th. The biotechnology company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.29). ADMA Biologics had a negative return on equity of 76.26% and a negative net margin of 35.00%. The firm had revenue of $3.40 million for the quarter, compared to analyst estimates of $3.52 million. sell-side analysts predict that ADMA Biologics will post -2.25 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This article was originally published by American Banking News and is the property of of American Banking News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this article can be accessed at

In related news, insider Adam S. Grossman acquired 485,000 shares of the stock in a transaction dated Thursday, November 9th. The stock was purchased at an average cost of $2.15 per share, with a total value of $1,042,750.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Eric I. Richman acquired 25,000 shares of the stock in a transaction dated Thursday, November 9th. The stock was bought at an average cost of $2.15 per share, with a total value of $53,750.00. Following the completion of the purchase, the director now owns 31,300 shares of the company’s stock, valued at $67,295. The disclosure for this purchase can be found here. Over the last three months, insiders bought 526,500 shares of company stock valued at $1,131,975. Company insiders own 60.44% of the company’s stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.

Receive News & Ratings for ADMA Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics Inc and related companies with's FREE daily email newsletter.